Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2007.5.1 | Award Amount: 21.96M | Year: 2008
Each year Cardiovascular Disease (CVD) causes over 1.9 million deaths in the EU, causing direct health costs of 105 billion. Coronary Heart Disease (CHD), half of all CVD deaths, is the single most cause of death in Europe. Heart Failure (HF) a CHD being the most frequent cause of hospitalization for people over 65 has 10 million patients in the EU. Current treatment of HF entails recommendations from clinicians on medication, diet and lifestyle. Patients only receive feedback at doctors visits, or when facing symptoms. Daily monitoring, close follow up, and help on treatment routine is lacking. Non-adherence to the treatment regime is a major cause of suboptimal clinical benefit.HeartCycle will provide a closed-loop disease management solution to serve both HF and CHD patients, including hypertension, diabetes and arrhythmias as possible co-morbidities. This will be achieved by multi-parametric monitoring of vital signs, analysing the data and providing automated decision support, to derive therapy recommendations.The system will contain a patient loop interacting directly with the patient to support the daily treatment. It will show the health development, including treatment adherence and effectiveness. Being motivated, compliance will increase, and health will improve. The system will also contain a professional loop involving medical professionals, e.g. alerting to revisit the care plan. The patient loop is connected with hospital information systems, to ensure optimal and personalised care.Europes health system is undergoing radical changes due to an aging population. Its moving from reactive towards preventative care, and from hospital care to care at home. Tomorrows patients will become more empowered to take their health into their own hands. New ICT is required to enable this paradigm shift.HeartCycle, coordinated by Philips leading in electronics and health care , includes experts on textiles, ICT, decision support and user interaction.
Astaras A.,Aristotle University of Thessaloniki |
Kokonozi A.,Aristotle University of Thessaloniki |
Michail E.,Aristotle University of Thessaloniki |
Filos D.,Aristotle University of Thessaloniki |
And 9 more authors.
IFMBE Proceedings | Year: 2010
Non-invasive monitoring of a patient's vital signs outside the medical centre is essential for the remote management of chronic cardiovascular diseases (CVD), such as Heart Failure (HF) and Coronary Artery Disease (CAD). In this work we present preliminary results from pre-clinical testing of the IMAGE sensing platform, a wearable device designed for wireless real-time data acquisition and monitoring of CVD patients' physiological responses, primarily while they are exercising. The device is capable of acquiring and on-board processing 3-lead electrocardiogram (ECG) and bioimpedance measurements, obtain multi-sensor oxymetry data as well as record torso movement and inclination. Pilot testing has so far primarily focused on optimising the hardware and experimental protocol, using healthy volunteers. A planned clinical study involving CVD patients is expected to commence within the next few months and provide more detailed experimental results, as part of a research and development effort into realtime exercise guidance and early-warning alert generation for patients and clinicians. The IMAGE device has been developed by CSEM SA, a partner in the HeartCycle consortium, a biomedical engineering project co-funded by the EU 7th Framework Programme. © 2010 International Federation for Medical and Biological Engineering.
Ulbrich M.,RWTH Aachen |
Muhlsteff J.,HIGH-TECH |
Sipila A.,Clothing Plus Oy |
Kamppi M.,Clothing Plus Oy |
And 5 more authors.
Physiological Measurement | Year: 2014
Measurement of hemodynamic parameters such as stroke volume (SV) via impedance cardiography (ICG) is an easy, non-invasive and inexpensive way to assess the health status of the heart. We present a possibility to use this technology for monitoring risk patients at home. The IMPACT Shirt (IMPedAnce Cardiography Textile) has been developed with integrated textile electrodes and textile wiring, as well as with portable miniaturized hardware. Several textile materials were characterized in vitro and in vivo to analyze their performance with regard to washability, and electrical characteristics such as skin-electrode impedance, capacitive coupling and subjective tactile feeling. The small lightweight hardware measures ECG and ICG continuously and transmits wireless data via Bluetooth to a mobile phone (Android) or PC for further analysis. A lithium polymer battery supplies the circuit and can be charged via a micro-USB. Results of a proof-of-concept trial show excellent agreement between SV assessed by a commercial device and the developed system. The IMPACT Shirt allows monitoring of SV and ECG on a daily basis at the patient's home. © 2014 Institute of Physics and Engineering in Medicine.